

Quarterly activities report for July – September 2016

The quarterly activities include details of monitoring and compliance activities by the Office of the Gene Technology Regulator (OGTR) during the quarter.

Monitoring of GMO Dealings involving Intentional Release (DIR)

During the quarter OGTR inspected **15 GM plant field trial sites** (Table 1).

The inspections comprised:

Current field trial sites: Of the 42 sites current in the quarter, five were inspected. This represents a monitoring rate of **12 per cent** of all current sites for the quarter.

Post-harvest field trial sites: Of the 67 sites subject to post-harvest monitoring in the quarter, 10 were inspected. This represents an inspection rate of **15 per cent** of all sites subject to post-harvest monitoring in this quarter.

Table 1 – Summary of inspection activities of GM crop field trials for the July – September 2016 quarter.

| Licence holder | Licence Number | GM Crop | Site location (crop status ¹) |
|---|----------------|--------------|---|
| Go Resources | DIR 131 | Safflower | Narrabri (c, p) |
| Monsanto Australia Ltd | DIR 120 | Cotton | Goondiwindi (p) Moree Plains (p) Narrabri (p) |
| Nuseed Pty Ltd | DIR 123 | Canola | Ararat (c, p) Horsham (c) |
| Victorian Department of Economic Development, Jobs, Transport and Resources | DIR 089 | White clover | Corowa (p) |

¹c=current site, p = post-harvest sited

Monitoring of GMO Dealings Not involving Intentional Release (DNIR) and certified facilities

During the quarter OGTR inspected eight organisations holding certified facilities (Table 2) and five organisations undertaking DNIR licences (Table 3).

Table 2 – Summary of organisations and facility types that the OGTR inspected for the July – September 2016 quarter.

| Organisation | Physical Containment (PC) level | Number of facilities monitored |
|--|--|---------------------------------------|
| Barwon Health, VIC | PC2 facility | 1 |
| Charles Sturt University, NSW | PC2 facility | 6 |
| CSIRO, VIC | PC3 facility | 1 |
| EnGeneIC Ltd, NSW | PC2 facility | 1 |
| Olivia Newton John Cancer Research Institute | PC2 facility | 3 |
| | PC3 facility | 1 |
| RMIT University | PC2 facility | 1 |
| TREIDLIA BIOVET Pty Ltd, NSW | PC2 facility | 1 |
| Victoria University, VIC | PC2 facility | 2 |
| Total | | 17 |

Table 3 – Summary of inspection activities for DNIR licences for July – September 2016 quarter.

| Licence holder | Licence Number |
|------------------------------|-----------------------|
| Amgen, VIC | DNIR 461 |
| | DNIR 559 |
| Deakin University, VIC | DNIR 512 |
| EnGeneIC Ltd, NSW | DNIR 261 |
| RMIT University | DNIR 560 |
| TREIDLIA BIOVET Pty Ltd, NSW | DNIR 549 |
| Total | 6 |

There were no practice reviews, audits and investigations completed in the quarter.

Monitoring and Compliance Findings

Findings from routine monitoring, auditing and investigations, and related enforcement activities, will be provided in the Regulator's Annual Report in accordance with section 136 of the *Gene Technology Act 2000*.